HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader

BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and m

BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Sci

BIO-key's (BKYI)Bottom Line Improves 51% on 13% Rise in Q2 Revenues Reflecting Strength with Governm

First Trust Advisors LP reduced its stake in shares of Bio-Rad Laboratories, Inc. (NYSE: BIO) by 97.

KUALA LUMPUR, MALAYSIA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS

Explore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's fore

Portuguese national security agency selects BIO-key (BKYI) and Visualforma to strengthen identity se

RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and r

HOLMDEL, N.J., Aug. 07, 2026 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ: BKYI), a globa

BIO-key's proven IAM platform and Maktabi Tech's education market leadership bring global best pract

Citigroup analyst Daniel Grosslight maintains Bio-Rad Laboratories (NYSE:BIO) with a Neutral and

RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and r

Wells Fargo analyst Evan Stampler maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight a

Amundi grew its position in Bio-Rad Laboratories, Inc. (NYSE: BIO) by 1,763.4% in the undefined quar

Bio-Rad Laboratories NYSE: BIO reported second-quarter revenue of approximately $651 million, essent

Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.62 per share, beating the Zacks Co

Bio-Rad Laboratories (NYSE:BIO) lowers FY2026 sales outlook from $2.506 billion-$2.596 billion to $2

Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.62 per share which beat the analys

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader

On July 28, 2026, Bio-Rad Laboratories Inc (BIO) shares rose 4.6% to $331.00, continuing a strong up

Central Bank of Jordan Selects BIO-key for National Biometric Authentication, Aiming to Advance Biom

20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tok

On July 23, 2026, Bio-Rad Laboratories Inc (BIO) shares rose 3.4%, bringing the current price to $31

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader

Taipei, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq

Elliott Management builds a stake in Bio-Rad (NYSE: BIO) to push for better performance, but family

Nasdaq sinks 1.1% as AMAT, MU, ORCL and Vertiv crater on AI capex jitters, while WTI tops $106 and t

TOYO shares rose 13.7% after beating earnings expectations. Other top gainers include JLHL, RAMP, HI

https://www.wsj.com/business/deals/activist-elliott-builds-big-stake-in-life-science-tools-supplier-

RBC Capital analyst Dan Leonard reinstates Bio-Rad Laboratories (NYSE:BIO) with a Outperform and

U.S. stocks hit fresh records as Apple's blowout Q2 powered Big Tech, while crude oil sank 3% on

Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weig

Bio-Rad Laboratories (NYSE:BIO) lowers FY2026 sales outlook from $2.596 billion-$2.622 billion to $2

Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $1.89 per share which missed the anal

Citigroup analyst Patrick Donnelly downgrades Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral

Full-Year 2026 Financial OutlookBio-Rad is providing its financial outlook for the full-year 2026. T

Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.51 per share which missed the anal

Qiagen is reviewing strategic options, including a potential sale, after renewed takeover interest f

Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and raise

Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weig

Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.26 per share which beat the analys

Full-Year 2025 Financial OutlookBio-Rad is maintaining its financial outlook for the full year 2025.